A single amino acid substitution in the S1 and S2 Spike protein domains determines the neutralization escape phenotype of SARS-CoV

Microbes and Infection

Volumn 10, Issue 8, 2008, Pages 908-915

  Mitsuki, Yu ya ^a,b   Ohnishi, Kazuo ^a   Takagi, Hirotaka ^a   Oshima, Masamichi ^a   Yamamoto, Takuya ^a   Mizukoshi, Fuminori ^a   Terahara, Kazutaka ^a   Kobayashi, Kazuo ^a   Yamamoto, Naoki ^a,b   Yamaoka, Shoji ^b   Tsunetsugu Yokota, Yasuko ^a  

^a NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

^b TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

Escape mutants; Neutralizing antibody; Passive immunotherapy; SARS CoV

Indexed keywords

COMPLEMENTARY DNA; IMMUNOGLOBULIN G1; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; VIRUS PROTEIN; VIRUS RNA; VIRUS SPIKE PROTEIN;

AMINO ACID SUBSTITUTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; IMMUNOTHERAPY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PASSIVE IMMUNIZATION; PHENOTYPE; PRIORITY JOURNAL; PROTEIN ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SARS CORONAVIRUS; SEVERE ACUTE RESPIRATORY SYNDROME; VIRUS INFECTION;

AMINO ACID SUBSTITUTION; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, VIRAL; MEMBRANE GLYCOPROTEINS; MICE; MUTATION, MISSENSE; NEUTRALIZATION TESTS; PLAQUE ASSAY; PROTEIN STRUCTURE, TERTIARY; SARS VIRUS; VIRAL ENVELOPE PROTEINS; VIRUS REPLICATION;

MUS; SARS CORONAVIRUS;

EID: 48549103591     PISSN: 12864579     EISSN: 1769714X     Source Type: Journal    
DOI: 10.1016/j.micinf.2008.05.009     Document Type: Article

References (28)

1. Rota P.A., Oberste M.S., Monroe S.S., Nix W.A., Campagnoli R., Icenogle J.P., Penaranda S., Bankamp B., Maher K., Chen M.H., Tong S., Tamin A., Lowe L., Frace M., DeRisi J.L., Chen Q., Wang D., Erdman D.D., Peret T.C., Burns C., Ksiazek T.G., Rollin P.E., Sanchez A., Liffick S., Holloway B., Limor J., McCaustland K., Olsen-Rasmussen M., Fouchier R., Gunther S., Osterhaus A.D., Drosten C., Pallansch M.A., Anderson L.J., and Bellini W.J. Characterization of a novel coronavirus associated with severe acute respiratory syndrome. Science 300 (2003) 1394-1399
2. Li F., Li W., Farzan M., and Harrison S.C. Structure of SARS coronavirus spike receptor-binding domain complexed with receptor. Science 309 (2005) 1864-1868
3. Liu S., Xiao G., Chen Y., He Y., Niu J., Escalante C.R., Xiong H., Farmar J., Debnath A.K., Tien P., and Jiang S. Interaction between heptad repeat 1 and 2 regions in spike protein of SARS-associated coronavirus: implications for virus fusogenic mechanism and identification of fusion inhibitors. Lancet 363 (2004) 938-947
4. Wong S.K., Li W., Moore M.J., Choe H., and Farzan M. A 193-amino acid fragment of the SARS coronavirus S protein efficiently binds angiotensin-converting enzyme 2. J. Biol. Chem. 279 (2004) 3197-3201
5. Li W., Moore M.J., Vasilieva N., Sui J., Wong S.K., Berne M.A., Somasundaran M., Sullivan J.L., Luzuriaga K., Greenough T.C., Choe H., and Farzan M. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature 426 (2003) 450-454
6. Li G., Chen X., and Xu A. Profile of specific antibodies to the SARS-associated coronavirus. N. Engl. J. Med. 349 (2003) 508-509
7. Tsunetsugu-Yokota Y., Ohnishi K., and Takemori T. Severe acute respiratory syndrome (SARS) coronavirus: application of monoclonal antibodies and development of an effective vaccine. Rev. Med. Virol. 16 (2006) 117-131
8. Greenough T.C., Babcock G.J., Roberts A., Hernandez H.J., Thomas Jr. W.D., Coccia J.A., Graziano R.F., Srinivasan M., Lowy I., Finberg R.W., Subbarao K., Vogel L., Somasundaran M., Luzuriaga K., Sullivan J.L., and Ambrosino D.M. Development and characterization of a severe acute respiratory syndrome-associated coronavirus-neutralizing human monoclonal antibody that provides effective immunoprophylaxis in mice. J. Infect. Dis. 191 (2005) 507-514
9. Sainz Jr. B., Rausch J.M., Gallaher W.R., Garry R.F., and Wimley W.C. Identification and characterization of the putative fusion peptide of the severe acute respiratory syndrome-associated coronavirus spike protein. J. Virol. 79 (2005) 7195-7206
10. Zwick M.B., Jensen R., Church S., Wang M., Stiegler G., Kunert R., Katinger H., and Burton D.R. Anti-human immunodeficiency virus type 1 (HIV-1) antibodies 2F5 and 4E10 require surprisingly few crucial residues in the membrane-proximal external region of glycoprotein gp41 to neutralize HIV-1. J. Virol. 79 (2005) 1252-1261
11. Lai S.C., Chong P.C., Yeh C.T., Liu L.S., Jan J.T., Chi H.Y., Liu H.W., Chen A., and Wang Y.C. Characterization of neutralizing monoclonal antibodies recognizing a 15-residues epitope on the spike protein HR2 region of severe acute respiratory syndrome coronavirus (SARS-CoV). J. Biomed. Sci. 12 (2005) 711-727
12. Lip K.M., Shen S., Yang X., Keng C.T., Zhang A., Oh H.L., Li Z.H., Hwang L.A., Chou C.F., Fielding B.C., Tan T.H., Mayrhofer J., Falkner F.G., Fu J., Lim S.G., Hong W., and Tan Y.J. Monoclonal antibodies targeting the HR2 domain and the region immediately upstream of the HR2 of the S protein neutralize in vitro infection of severe acute respiratory syndrome coronavirus. J. Virol. 80 (2006) 941-950
13. Zhang H., Wang G., Li J., Nie Y., Shi X., Lian G., Wang W., Yin X., Zhao Y., Qu X., Ding M., and Deng H. Identification of an antigenic determinant on the S2 domain of the severe acute respiratory syndrome coronavirus spike glycoprotein capable of inducing neutralizing antibodies. J. Virol. 78 (2004) 6938-6945
14. Zhong X., Yang H., Guo Z.F., Sin W.Y., Chen W., Xu J., Fu L., Wu J., Mak C.K., Cheng C.S., Yang Y., Cao S., Wong T.Y., Lai S.T., Xie Y., and Guo Z. B-cell responses in patients who have recovered from severe acute respiratory syndrome target a dominant site in the S2 domain of the surface spike glycoprotein. J. Virol. 79 (2005) 3401-3408
15. Takasuka N., Fujii H., Takahashi Y., Kasai M., Morikawa S., Itamura S., Ishii K., Sakaguchi M., Ohnishi K., Ohshima M., Hashimoto S., Odagiri T., Tashiro M., Yoshikura H., Takemori T., and Tsunetsugu-Yokota Y. A subcutaneously injected UV-inactivated SARS coronavirus vaccine elicits systemic humoral immunity in mice. Int. Immunol. 16 (2004) 1423-1430
16. Ohnishi K., Sakaguchi M., Kaji T., Akagawa K., Taniyama T., Kasai M., Tsunetsugu-Yokota Y., Oshima M., Yamamoto K., Takasuka N., Hashimoto S., Ato M., Fujii H., Takahashi Y., Morikawa S., Ishii K., Sata T., Takagi H., Itamura S., Odagiri T., Miyamura T., Kurane I., Tashiro M., Kurata T., Yoshikura H., and Takemori T. Immunological detection of severe acute respiratory syndrome coronavirus by monoclonal antibodies. Jpn. J. Infect. Dis. 58 (2005) 88-94
17. Ishii K., Hasegawa H., Nagata N., Mizutani T., Morikawa S., Suzuki T., Taguchi F., Tashiro M., Takemori T., Miyamura T., and Tsunetsugu-Yokota Y. Induction of protective immunity against severe acute respiratory syndrome coronavirus (SARS-CoV) infection using highly attenuated recombinant vaccinia virus DIs. Virology 351 (2006) 368-380
18. Yoo D., and Deregt D. A single amino acid change within antigenic domain II of the spike protein of bovine coronavirus confers resistance to virus neutralization. Clin. Diagn. Lab. Immunol. 8 (2001) 297-302
19. Chen Z., Zhang L., Qin C., Ba L., Yi C.E., Zhang F., Wei Q., He T., Yu W., Yu J., Gao H., Tu X., Gettie A., Farzan M., Yuen K.Y., and Ho D.D. Recombinant modified vaccinia virus Ankara expressing the spike glycoprotein of severe acute respiratory syndrome coronavirus induces protective neutralizing antibodies primarily targeting the receptor binding region. J. Virol. 79 (2005) 2678-2688
20. He Y., Zhu Q., Liu S., Zhou Y., Yang B., Li J., and Jiang S. Identification of a critical neutralization determinant of severe acute respiratory syndrome (SARS)-associated coronavirus: importance for designing SARS vaccines. Virology 334 (2005) 74-82
21. Shih Y.P., Chen C.Y., Liu S.J., Chen K.H., Lee Y.M., Chao Y.C., and Chen Y.M. Identifying epitopes responsible for neutralizing antibody and DC-SIGN binding on the spike glycoprotein of the severe acute respiratory syndrome coronavirus. J. Virol. 80 (2006) 10315-10324
22. Yi C.E., Ba L., Zhang L., Ho D.D., and Chen Z. Single amino acid substitutions in the severe acute respiratory syndrome coronavirus spike glycoprotein determine viral entry and immunogenicity of a major neutralizing domain. J. Virol. 79 (2005) 11638-11646
23. Sui J., Li W., Murakami A., Tamin A., Matthews L.J., Wong S.K., Moore M.J., Tallarico A.S., Olurinde M., Choe H., Anderson L.J., Bellini W.J., Farzan M., and Marasco W.A. Potent neutralization of severe acute respiratory syndrome (SARS) coronavirus by a human mAb to S1 protein that blocks receptor association. Proc. Natl. Acad. Sci. USA 101 (2004) 2536-2541
24. Pearson H., Clarke T., Abbott A., Knight J., and Cyranoski D. SARS: what have we learned?. Nature 424 (2003) 121-126
25. Coughlin M., Lou G., Martinez O., Masterman S.K., Olsen O.A., Moksa A.A., Farzan M., Babcook J.S., and Prabhakar B.S. Generation and characterization of human monoclonal neutralizing antibodies with distinct binding and sequence features against SARS coronavirus using XenoMouse. Virology 361 (2007) 93-102
26. Rockx B., Corti D., Donaldson E., Sheahan T., Stadler K., Lanzavecchia A., and Baric R. Structural basis for potent cross-neutralizing human monoclonal antibody protection against lethal human and zoonotic severe acute respiratory syndrome coronavirus challenge. J. Virol. 82 (2008) 3220-3235
27. Zhu Z., Chakraborti S., He Y., Roberts A., Sheahan T., Xiao X., Hensley L.E., Prabakaran P., Rockx B., Sidorov I.A., Corti D., Vogel L., Feng Y., Kim J.O., Wang L.F., Baric R., Lanzavecchia A., Curtis K.M., Nabel G.J., Subbarao K., Jiang S., and Dimitrov D.S. Potent cross-reactive neutralization of SARS coronavirus isolates by human monoclonal antibodies. Proc. Natl. Acad. Sci. USA 104 (2007) 12123-12128
28. ter Meulen J., van den Brink E.N., Poon L.L., Marissen W.E., Leung C.S., Cox F., Cheung C.Y., Bakker A.Q., Bogaards J.A., van Deventer E., Preiser W., Doerr H.W., Chow V.T., de Kruif J., Peiris J.S., and Goudsmit J. Human monoclonal antibody combination against SARS coronavirus: synergy and coverage of escape mutants. PLoS. Med. 3 (2006) e237